IRLAB Therapeutics AB

IRLAB A

SE0012675361

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:43 2024-05-31 EDT			5-day change	1st Jan Change
15.6 ^SEK	-0.95%		-1.27%	+108.00%

05-27	Sweden’s IRLAB Therapeutics Names New CEO	MT
05-27	IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024	CI

IRLAB Therapeutics AB Announces Board Changes

December 31, 2021 at 04:30 am

IRLAB Therapeutics AB announced that Martin Nicklasson intends to leave the board in January 2022. The background to this decision is his new role as chairman of the board in another company.

Latest news about IRLAB Therapeutics AB

Sweden’s IRLAB Therapeutics Names New CEO	05-27	MT
IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024	05-27	CI
IRLAB Therapeutics AB Strengthens Liquidity by Drawing SEK 25 Million on A Previously Secured Loan Facility	05-23	CI
IRLAB Therapeutics AB Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757	05-22	CI
Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024	05-08
IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	05-07	CI
IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757	05-06	CI
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	03-22	CI
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	03-19	CI
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	02-22	CI
Transcript : IRLAB Therapeutics AB, 2023 Earnings Call, Feb 07, 2024	02-07
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-07	CI
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	02-06	CI
IRLAB Therapeutics AB(OM:IRLAB A) added to OMX Nordic Small Cap Index	01-04	CI
Irlab Therapeutics to Meet with US FDA for Mesdopetam Progam in February	01-03	MT
IRLAB Is Granted an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	01-03	CI
IRLAB Therapeutics AB Receives Grant from the Michael J. Fox Foundation to Support Development of IRL 757 for the Treatment of Apathy	12-21	CI
IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I	12-21	CI
IRLAB Therapeutics AB Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	12-18	CI
Irlab Therapeutics Secures European Patent for Parkinson’s Disease Drug Candidate	12-12	MT
IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection	12-12	CI
IRLAB Therapeutics AB Announces Appointment to its Nomination Committee	11-07	CI
Transcript : IRLAB Therapeutics AB, Nine Months 2023 Earnings Call, Oct 25, 2023	23-10-25
IRLAB Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-25	CI

IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâs disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâs Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Sector

Pharmaceuticals

Calendar

2024-07-10 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for IRLAB Therapeutics AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IRLAB THERAPEUTICS AB	+108.00%	77.14M
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B

Other Pharmaceuticals